Repositioning Candidate Details
| Candidate ID: | R0740 |
| Source ID: | DB05218 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | PN0621 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Intended for the treatment of auto-immune diseases such as rheumatoid arthritis, psoriasis and Crohn's disease. |
| DrugBank Pharmacology: | PN0621 is an anti-TNF, a name given to a class of drugs being developed for the treatment of auto-immune diseases such as rheumatoid arthritis, psoriasis and Crohn's disease. |
| DrugBank MoA: | Auto-immune diseases are indicated where an individual's immune system mistakenly attacks the body's own tissues. PN0621 works by blocking the action of TNF (tumour necrosis factor) which is involved in this attack. |
| Targets: | Tumor necrosis factor |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |